{"id":1009195,"date":"2026-10-12T08:06:29","date_gmt":"2026-10-12T12:06:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/"},"modified":"2026-10-12T08:06:29","modified_gmt":"2026-10-12T12:06:29","slug":"imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/","title":{"rendered":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings"},"content":{"rendered":"
\n

NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management.<\/p>\n

The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med.\u00a0Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin. Charit\u00e9 in Berlin is one of the world\u2019s leading academic medical institutions, a European leader in transplantation, and the home of Germany\u2019s largest kidney transplant program.<\/p>\n

Dr. Budde brings firsthand clinical insight into the expanding role of molecular diagnostics in transplant care. He initiated the Phase 2 felzartamab study published <\/a>in the New England Journal of Medicine<\/a> in 2024, which used iMDx\u2019s GraftAssure dd-cfDNA technology to monitor kidney transplant injury during treatment for antibody-mediated rejection. In the extension study published<\/a> recently in Lancet Regional Health Europe<\/a>, GraftAssure was used to guide felzartamab therapy. His group has published numerous studies on the use of dd-cfDNA in various clinical situations.<\/p>\n

Dr. Budde\u2019s discussion with iMDx\u2019s CEO and with BTIG analyst Mark Massaro will explore the potential for GraftAssure, including how localized, blood-based testing could help physicians assess treatment response, identify recurrence, and ultimately tailor anti-rejection therapy to individual patients.<\/p>\n

\n Event:<\/strong>\u00a0U.S. Bancorp I BTIG Kidney Health Forum
Format: <\/strong>Virtual KOL discussion and 1×1 meetings with iMDx management
KOL discussion date and time:<\/strong> Wednesday, October 14, 2026, at 12:00 pm ET
Speakers: <\/strong>iMDx CEO Josh Riggs and Charite\u2019s Prof. Dr. Med. Klemens Budde<\/p>\n

Insight Molecular Diagnostics Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will also conduct virtual one-on-one meetings during the conference. Investors wishing to meet with iMDx management are encouraged to reach out to their US Bancorp I BTIG sales representative.<\/p>\n

\n About Key Opinion Leader Prof. Dr. Med. Klemens Budde<\/strong>
\n
Prof. Dr. Med. Klemens Budde is senior physician in the Medical Clinic with focus on transplant nephrology, Charit\u00e9 University Medicine Berlin. In 2006 he was appointed full professor for Pharmacodynamics of Immunosuppression after Kidney Transplantation. After graduating in medicine at the University of T\u00fcbingen and a 2-year research stay at Yale University, New Haven, Connecticut\/USA, Prof. Budde started his clinical training at the Friedrich-Alexander-University Erlangen-Nuremberg and completed it at the Charit\u00e9. He is a specialist in internal medicine and nephrology and has the additional qualification of hypertensiologist. His scientific focus is on all clinical aspects of transplantation medicine. Prof. Budde is consortium leader of the \u201cMACSS\u201d project, which is funded by the Federal Ministry of Economics. Since 2018, he has been head of the Health Working Group of the Learning Systems Platform, the German platform for artificial intelligence, which is funded by the Federal Ministry of Education and Research.<\/p>\n

\n About\u00a0Insight Molecular Diagnostics Inc.<\/strong>
\n
Insight Molecular Diagnostics\u00a0is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit\u00a0https:\/\/investors.imdxinc.com\/<\/a>\u00a0for more information.<\/p>\n

GraftAssureCore\u2122, GraftAssureIQ\u2122, GraftAssureDx\u2122, VitaGraft\u2122, GraftAssure\u2122, DetermaIO\u2122, and DetermaCNI\u2122 are trademarks of\u00a0Insight Molecular Diagnostics Inc.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Any statements that are not historical fact (including, but not limited to, statements that contain words such as \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cmay,\u201d and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, iMDx\u2019s expected participation at the U.S. Bancorp I BTIG Kidney Health Forum, anticipated KOL virtual discussion featuring Josh Riggs and Dr. Budde, the potential of GraftAssure, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.<\/p>\n

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and\/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics\u2019 third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients\u2019 use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the \u201cRisk Factors\u201d and other cautionary statements found in Insight Molecular Diagnostics\u2019 Securities and Exchange Commission (SEC) filings, which are available from the SEC\u2019s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\u202f\u202f<\/p>\n

\n FDA<\/strong>\n <\/p>\n

\n CAUTION:<\/strong> This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.<\/p>\n

\n Investor Contact:<\/strong>
\n
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management. The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med.\u00a0Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin. Charit\u00e9 in Berlin is one of the world\u2019s leading academic medical institutions, a European leader in transplantation, and the home of Germany\u2019s largest kidney … <\/p>\n

Continue reading “iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\niMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management. The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med.\u00a0Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin. Charit\u00e9 in Berlin is one of the world\u2019s leading academic medical institutions, a European leader in transplantation, and the home of Germany\u2019s largest kidney … Continue reading "iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-12T12:06:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings\",\"datePublished\":\"2026-10-12T12:06:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/\"},\"wordCount\":1002,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/\",\"name\":\"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==\",\"datePublished\":\"2026-10-12T12:06:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/","og_locale":"en_US","og_type":"article","og_title":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk","og_description":"NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management. The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med.\u00a0Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin. Charit\u00e9 in Berlin is one of the world\u2019s leading academic medical institutions, a European leader in transplantation, and the home of Germany\u2019s largest kidney … Continue reading \"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-12T12:06:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings","datePublished":"2026-10-12T12:06:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/"},"wordCount":1002,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/","name":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==","datePublished":"2026-10-12T12:06:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzEzOCM3ODg4NTUwIzUwMDA1MTg5MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imdx-to-participate-in-virtual-u-s-bancorp-i-btig-kidney-health-forum-with-kol-discussion-and-investor-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}